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maintenance gefitinib in patients with 
advanced non–small-cell lung cancer 
without disease progression after first-
line chemotherapy. In terms of the results, 
maintenance treatment with gefitinib 
significantly improved OS compared 
with placebo in epidermal growth fac-
tor receptor (EGFR) mutation-positive 
patients, whereas there was no survival 
difference between gefitinib and pla-
cebo in mutation-negative or unknown 
patients.1 Should we use gefitinib as 
maintenance therapy for mutation-
positive patients once disease control is 
achieved after first-line chemotherapy?
In the first place, EGFR muta-
tion analysis was conducted in only 30 
patients (10%) in the study. In addi-
tion, 47% of the patients assigned 
to the placebo group never received 
any EGFR tyrosine kinase inhibitors 
(TKIs) as their post-study treatment, 
which may have affected the results. 
The preceding SATURN study failed to 
demonstrate an OS benefit in mutation-
positive patients, which may have been 
due to extensively high cross-over in 
the placebo group.2 Considering that 
EGFR-TKI is similarly effective in the 
second-line setting3 and that it some-
times causes fatal adverse events, such 
as interstitial lung disease,4 we should 
be cautious over the use of EGFR-TKI 
as maintenance treatment after chemo-
therapy in mutation-positive patients.
On the other hand, subgroup anal-
yses of the SATURN study suggested 
that maintenance EGFR-TKI may 
lead to significant OS improvement in 
mutation-positive patients who achieve 
stable disease after first-line chemo-
therapy (hazard ratio [HR]: 0.48; 95% 
confidence interval [CI]: 0.14–1.62).2 
Considering that patients with a smaller 
decrease in target lesions are also less 
likely to receive subsequent treatment,5 
an earlier start of EGFR-TKI may be 
beneficial in patients with a mutation-
positive status and stable disease fol-
lowing first-line chemotherapy.
Recently, mutation analyses 
including EGFR have routinely been 
performed before first-line treatment in 
patients with advanced non–small-cell 
lung cancer in many cases, and EGFR-
TKI is usually selected as a first-line 
treatment for EGFR mutation-positive 
patients. In such patients, continuation 
EGFR-TKI beyond disease progres-
sion may prolong OS6, while it may 
lead to decrease the opportunity to 
receive effective chemotherapy and 
compromise the survival as a result. 
Continuation of gefitinib in combina-
tion with chemotherapy did not improve 
progression-free survival and rather 
compromised OS compared with che-
motherapy alone.7 Optimal timing to 
change treatments from EGFR-TKI to 
chemotherapy is another and more cru-
cial issue to be resolved.
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In Response:
First, we thank Drs. Young Hak 
Kim and Michiaki Mishima for care-
fully reviewing our Iressa in NSCLC 
FOR Maintenance study INFORM) 
overall survival (OS) article, and we 
also thank the editors of the Journal of 
Thoracic Oncology for giving us a very 
precious opportunity to discuss many 
interesting issues with our counterparts 
around the world.
Regarding the first issue, 
INFORM study results did not sup-
port the routine use of epidermal 
growth factor receptor tyrosine kinase 
inhibitors (EGFR-TKIs) for mainte-
nance treatment as a standard of care 
in all patients with advanced non–
small-cell lung cancer (NSCLC). 
We agree with Dr. Kim that the sub-
groups with mutation-positive and 
mutation-negative patients in the 
INFORM study were small (n = 79). 
Moreover, the crossover rate in the 
INFORM study was lower than that 
in the  phase 3,  placebo-controlled 
Sequential Tarceva in Unresectable 
NSCLC (SATURN) study (67% ver-
sus 53%).1 This may explain the dif-
ference in OS result between our 
INFORM study and the SATURN 
study in mutation-positive patients. On 
the other hand, we do not agree with 
Dr. Kim’s argument about the overuse 
of maintenance treatment for patients 
with EGFR mutation. First, previ-
ous first-line studies had proved that 
the first-line use of EGFR-TKIs in 
 mutation-positive patients was asso-
ciated with better progression-free 
survival and favorable toxicity profile 
when compared with first-line chemo-
therapy.2 However, none of these first-
line studies show OS benefit, and use of 
EGFR-TKIs still became the standard 
of care for first-line treatment of these 
mutation-positive patients. Second, 
current data indicate that the risk of 
interstitial lung disease associated 
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the INFORM study reports the pro-
longation of OS in EGFR mutation-
positive patients; hence, we strongly 
suggest to conduct a large-scale, ran-
domization phase III trial to compare 
the differences in OS between first-line 
EGFR-TKI treatment followed by che-
motherapy and first-line chemotherapy 
followed by maintenance treatment 
using EGFR-TKIs in patients with 
advanced NSCLC who have EGFR 
mutation-positive tumor.
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first-line, maintenance, or second-line 
treatments.3 In other words, mainte-
nance therapy using EGFR-TKIs for 
mutation-positive population is as safe 
as second-line treatment using EGFR-
TKIs. On the basis of these consider-
ations, European Society for Medical 
Oncology (ESMO) consensus also rec-
ommends patients to receive erlotinib as 
switch maintenance therapy after first-
line platinum-based chemotherapy.4
Regarding the second issue, in the 
INFORM study, we had analyzed the 
relationship between tumor response 
after first-line treatment and OS in the 
overall population and in EGFR muta-
tion–positive subgroups, but we did not 
find that stable disease (SD) after first-
line chemotherapy was a predictive 
factor for OS. Patients included in the 
INFORM study are totally East Asians, 
but most patients in the SATURN study 
are whites (n = 746, 84%).1 Considering 
that Asian patients have greater fre-
quency of EGFR mutations compared 
with white patients,5–7 we believe that 
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outcome.
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chemotherapy. Previous eight studies 
of first-line EGFR-TKIs failed to find 
the differences in OS between EGFR-
TKIs and chemotherapy arms in EGFR 
mutation-positive patients,2 whereas 
multicenter diagnostic survey. J Thorac 
Oncol 2015;10:438–445.
 9. Xue C, Hu Z, Jiang W, et al. National survey 
of the medical treatment status for non-small 
cell lung cancer (NSCLC) in China. Lung 
Cancer 2012;77:371–375.
 10. Brodowicz T, Krzakowski M, Zwitter M, et 
al.; Central European Cooperative Oncology 
Group CECOG. Cisplatin and gemcitabine 
first-line chemotherapy followed by mainte-
nance gemcitabine or best supportive care in 
advanced non-small cell lung cancer: a phase 
III trial. Lung Cancer 2006;52:155–163.
 11. Ciuleanu T, Brodowicz T, Zielinski C, 
et al. Maintenance pemetrexed plus best 
supportive care versus placebo plus best 
supportive care for non-small-cell lung 
cancer: a randomised, double-blind, phase 3 
study. Lancet 2009;374:1432–1440.
 12. Fidias PM, Dakhil SR, Lyss AP, et al. Phase 
III study of immediate compared with delayed 
docetaxel after front-line therapy with gem-
citabine plus carboplatin in advanced non-small-
cell lung cancer. J Clin Oncol 2009;27:591–598.
DOI: 10.1097/JTO.0000000000000605
Copyright © 2015 by the International Association 
for the Study of Lung Cancer
ISSN: 1556-0864/15/1008-0e83
Address for correspondence: Arnaud Uguen, MD, 
Department of Pathology, University Hospital 
Morvan, 5, Avenue Foch 29609 Brest, France. 
E-mail: arnaud.uguen@chu-brest.fr
Disclosure: The authors declare no conflicts of 
interest.
To the Editor:
We read with much interest the 
study by Rogers et al. concerning the 
use of fluorescence in situ (FISH), 
chromogenic in situ hybridization, and 
immunohistochemistry (IHC) for the 
detection of ALK and ROS1 rearrange-
ments in lung cancer.1 They concluded 
that FISH versus IHC showed good cor-
relation in the detection of ALK rear-
rangements but weak correlation in the 
detection of ROS1 rearrangements.
We would like to comment on 
this latter conclusion and emphasize 
the importance of FISH “home-made” 
